Healthcare Press Releases: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Press Releases.

Press releases published on September 14, 2026

Sep. 14, 2026

Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases

Indeterminate GlobeNewswire

Sep. 14, 2026

Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study

Indeterminate GlobeNewswire

Sep. 14, 2026

Beta Bionics Announces FDA Clearance of Mint™, the Company’s Transformative Patch Pump, and Unveils 3D Intelligence™ as its Next-Generation Insulin Dosing Algorithm

Indeterminate GlobeNewswire

Sep. 14, 2026

Cytokinetics Announces Call for Proposals for Ninth Annual Communications Grant Program 

Indeterminate GlobeNewswire

Sep. 14, 2026

As New York Fashion Week Kicks Off, Kraig Labs Advances Spider Silk for Fashion's Next Generation of Designers

Indeterminate GlobeNewswire

Sep. 14, 2026

Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma

Indeterminate GlobeNewswire

Sep. 14, 2026

Slate Medicines Appoints Kenneth Koblan, PhD, as Chief Scientific Officer

Indeterminate GlobeNewswire

Sep. 14, 2026

Soleo Health Expands Atlanta Footprint With Infusion Centers In Woodstock and Fayetteville, Georgia

Indeterminate GlobeNewswire

Sep. 14, 2026

Pharmazz, Inc. Receives U.S. FDA Orphan Drug Designation for Sovateltide for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy (NHIE)

Indeterminate GlobeNewswire

Sep. 14, 2026

Hop Valley Brewing Co. Makes Its Downtown Eugene Comeback with New Pub at 5th Street Public Market

Indeterminate GlobeNewswire

Sep. 14, 2026

Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference

Indeterminate GlobeNewswire

Sep. 14, 2026

Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development

Indeterminate GlobeNewswire

Sep. 14, 2026

Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification

Indeterminate GlobeNewswire

Sep. 14, 2026

INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board

Indeterminate GlobeNewswire

Sep. 14, 2026

Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer

Indeterminate GlobeNewswire

Sep. 14, 2026

Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity

Indeterminate GlobeNewswire

Sep. 14, 2026

Asimov Announces Cell Line Development Partnership with Sidewinder Therapeutics to Advance 4-Chain Bispecific Antibody for Solid Tumors

Indeterminate GlobeNewswire

Sep. 14, 2026

Senseonics Announces Strategic Partnership with Beta Bionics to Integrate Eversense® 365 with the iLet® Bionic Pancreas

Indeterminate GlobeNewswire

Sep. 14, 2026

Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference

Indeterminate GlobeNewswire

Sep. 14, 2026

Cyllene Therapeutics Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EG110A in Neurogenic Detrusor Overactivity (NDO)

Indeterminate GlobeNewswire